Anchiano Therapeutics Reports Second Quarter 2019 Financial Results
CAMBRIDGE, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) ("Anchiano"), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today reported financial results for its second quarter and six months ended June 30, 2019.
Key Developments and Recent Highlights
Appointed Salar Roshan as the Head of Business Development to focus on leading Anchiano's strategic initiatives. Delisted the c...